Diabetes Investment Portfolios

Pharmaceuticals
INHALE-3 Study Highlights the Efficacy of Inhaled Insulin Over Usual Care for Type 1 Diabetes Jun 23, 2024
Biopharmaceuticals
Initial Results of INHALE-3 Study: Afrezza® vs. Conventional Insulin Delivery Mar 12, 2024
Biotech
Biomea Fusion Reports Promising Results for Diabetes Treatment Candidate BMF-219 at WCIRDC Dec 8, 2023